B-type natriuretic peptide attenuates cardiac hypertrophy via the transforming growth factor-β1/smad7 pathway in vivo and in vitro

被引:32
作者
He, Jian-Gui [1 ]
Chen, Yi-Li [1 ]
Chen, Bai-Li [2 ]
Huang, Yi-Yi [3 ]
Yao, Feng-Juan [4 ]
Chen, Sheng-Long [1 ]
Dong, Yu-Gang [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Cardiol, Guangzhou 510080, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol, Guangzhou 510080, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Emergency, Guangzhou 510080, Guangdong, Peoples R China
[4] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Ultrasound, Guangzhou 510080, Guangdong, Peoples R China
关键词
B-type natriuretic peptide; cardiac hypertrophy; heart failure; myocardial infarction; transforming growth factor-beta 1; smad7; pathway; NITRIC-OXIDE SYNTHASE; GUANYLYL CYCLASE-A; FACTOR-BETA; TGF-BETA; MYOCARDIAL-INFARCTION; FIBROSIS; FIBROBLASTS; MECHANISMS; EXPRESSION; RECEPTOR;
D O I
10.1111/j.1440-1681.2009.05281.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
P>1. Previously, we showed that long-term treatment of rats after myocardial infarction (MI) with B-type natriuretic peptide (BNP) prevented ventricular remodelling. However, it is unclear whether long-term BNP treatment affects cardiac hypertrophy and, if so, its mechanism of action. In the present study, we investigated the effects of long-term BNP treatment on cardiac hypertrophy and the molecular mechanisms involved. 2. Cardiac hypertrophy was established in rats by ligation of the left anterior descending coronary artery. After treatment with BNP (5 or 15 mu g/kg per day) for 8 weeks, indices of cardiac hypertrophy were determined. In separate in vitro experiments, cardiomyocyte hypertrophy was induced by treatment of cardiomyocytes with 10-6 mol/L angiotensin (Ang) II for 48 h and cell surface area and [3H] incorporation were measured. Transforming growth factor (TGF)-beta 1 and smad7 mRNA and protein expression in vivo and in vitro were detected using reverse transcription-polymerase chain reaction and western blotting. 3. Long-term BNP treatment dose-dependently attenuated cardiac hypertrophy and improved cardiac function in rats after MI. Furthermore, BNP attenuated the upregulation of TGF-beta 1 and downregulation of smad7 mRNA and protein expression. The in vitro experiments further proved that BNP inhibited cardiac hypertrophy and changes in the TGF-beta 1/smad7 pathway, which were completely blocked by the cyclic GMP-dependent protein kinase (PKG) inhibitor, KT5823 (cells were treated with 10-6 mol/L KT5823 for 48 h). 4. The results of the present study demonstrate that long-term treatment of rats with BNP dose-dependently attenuates cardiac hypertrophy and that this is associated with downregulation of TGF-beta 1 and upregulation of smad7 via PKG signalling. Long-term BNP treatment may be a new therapeutic strategy to prevent cardiac hypertrophy and progression to heart failure.
引用
收藏
页码:283 / 289
页数:7
相关论文
共 34 条
  • [1] ECM remodeling in hypertensive heart disease
    Berk, Bradford C.
    Fujiwara, Keigi
    Lehoux, Stephanie
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (03) : 568 - 575
  • [2] Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice
    Bubikat, A
    De Windt, LJ
    Zetsche, B
    Fabritz, L
    Sickler, H
    Eckardt, D
    Gödecke, A
    Baba, HA
    Kuhn, M
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (22) : 21594 - 21599
  • [3] The role of TGF-β signaling in myocardial infarction and cardiac remodeling
    Bujak, Marcin
    Frangogiannis, Nikolaos G.
    [J]. CARDIOVASCULAR RESEARCH, 2007, 74 (02) : 184 - 195
  • [4] Chronic Actions of a Novel Oral B-Type Natriuretic Peptide Conjugate in Normal Dogs and Acute Actions in Angiotensin II-Mediated Hypertension
    Cataliotti, Alessandro
    Chen, Horng H.
    Schirger, John A.
    Martin, Fernando L.
    Boerrigter, Guido
    Costello-Boerrigter, Lisa C.
    James, Kenneth D.
    Polowy, Karen
    Miller, Mark A.
    Malkar, Navdeep B.
    Bailey, Kent R.
    Burnett, John C., Jr.
    [J]. CIRCULATION, 2008, 118 (17) : 1729 - 1736
  • [5] Oral brain natriuretic peptide: A novel strategy for chronic protein therapy for cardiovascular disease
    Cataliotti, Alessandro
    Chen, Horng H.
    James, Kenneth D.
    Burnett, John C., Jr.
    [J]. TRENDS IN CARDIOVASCULAR MEDICINE, 2007, 17 (01) : 10 - 14
  • [6] Hop is an unusual homeobox gene that modulates cardiac development
    Chen, F
    Kook, H
    Milewski, R
    Gitler, AD
    Lu, MM
    Li, J
    Nazarian, R
    Schnepp, R
    Jen, K
    Biben, C
    Runke, G
    Mackay, JP
    Novotny, J
    Schwartz, RJ
    Harvey, RP
    Mullins, MC
    Epstein, JA
    [J]. CELL, 2002, 110 (06) : 713 - 723
  • [7] Subcutaneous administration of brain natriuretic peptide in experimental heart failure
    Chen, HH
    Grantham, JA
    Schirger, JA
    Jougasaki, M
    Redfield, MM
    Burnett, JC
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (05) : 1706 - 1712
  • [8] Smad-dependent and Smad-independent pathways in TGF-β family signalling
    Derynck, R
    Zhang, YE
    [J]. NATURE, 2003, 425 (6958) : 577 - 584
  • [9] The complex pattern of SMAD signaling in the cardiovascular system
    Euler-Taimor, G
    Heger, J
    [J]. CARDIOVASCULAR RESEARCH, 2006, 69 (01) : 15 - 25
  • [10] Natriuretic peptides: markers or modulators of cardiac hypertrophy?
    Gardner, DG
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2003, 14 (09) : 411 - 416